Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I/II Study of Bosutinib in Combination With Inotuzumab Ozogamicin in CD22-Positive Philadelphia-Chromosome Positive Acute Lymphoblastic Leukemia and Chronic Myeloid Leukemia Lymphoid Blast Phase

NCT02311998 is registered in ClinicalTrials.gov with M.D. Anderson Cancer Center as lead sponsor.

NCT NCT02311998
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02311998 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I/II Study of Bosutinib in Combination With Inotuzumab Ozogamicin in CD22-Positive Philadelphia-Chromosome Positive Acute Lymphoblastic Leukemia and Chronic Myeloid Leukemia Lymphoid Blast Phase
Lead sponsor
M.D. Anderson Cancer Center
Phase
Phase 1/2
Overall status
Completed
Start date
April 16, 2015
Completion date
March 23, 2022
Enrollment
22 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

b acute lymphoblastic leukemia with t(9;22)(q34.1;q11.2); bcr-abl1, blast phase chronic myelogenous leukemia, bcr-abl1 positive, blasts more than 5 percent of bone marrow nucleated cells, cd22 positive, philadelphia chromosome positive, bcr-abl1 positive chronic myelogenous leukemia, recurrent chronic myelogenous leukemia, bcr-abl1 positive, refractory chronic myelogenous leukemia, bcr-abl1 positive